circRNA basic information
circBase ID: hsa_circ_0000190
Name: hsa_circ_CNIH4
Synonym: C190
Host Gene: CNIH4
Genomic location(hg19): chr1:224553580-224559125:+
Genomic location(hg38): chr1:224365878-224371423:+
Subcellular localization: cytoplasm
 
 
 
 
 
 
 
Disease basic information
MONDO ID:
 0005233
MONDO name: non-small cell lung carcinoma
Disease details: non-small cell lung cancer / NSCLC
Disease DO ID:
 3908
Disease MeSH ID:
 D002289
Disease NCIt ID:
 C2926
Disease ICD11 ID:
 -
Disease OMIM ID:
 -
Species: Human
Species details: Homo sapiens
Tissue specimen:

NSCLC tumor samples; adjacent normal lung tissue; primary lung adenocarcinoma; blood samples; xenograft tumor samples
Cell lines:

A549; HCC827; H1299; BEAS-2B
In vivo animal model:

cell line-derived xenograft
circRNA-disease information
Expression pattern:
UP
Associated gene: CDK1, CDK4, CDK6, p70S6K, RPS6, ERK1/2, Rb, cell-cycle and translationrelated proteins
Associated microRNA: miR-142-5p
Biological function: Promotes NSCLC cell proliferation, migration, anchorage-free survival, and xenograft tumor growth; CRISPR/Cas13a-mediated knockdown suppresses these pro-oncogenic properties.
Molecular mechanism: C190 is induced by EGFR activation through a MAPK/ERK-dependent mechanism, positively regulates ERK1/2 phosphorylation, activates cell-cycle and global translation-associated kinases, and sponges miR-142-5p to modulate CDK6 and CDK expression; it may also associate with cell-cycle and translation-related proteins.
Biological pathway or process:

EGFR (promotes); ERK (promotes); MAPK (promotes); proliferation (promotes); migration (promotes); invasion (promotes); cell cycle (promotes); mRNA stability (other); ceRNA regulation (promotes); other pathway/process (promotes)
Detected method:
Q
H
S
Validation methods:

Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; Actinomycin D / DRB Stability Assay; RT-qPCR; RNA-seq; FISH / smFISH; IF (Immunofluorescence); RNA Pull-Down; Luciferase Reporter Assay; Transfection; Colony Formation Assay; Wound Healing Assay; Transwell Assay; In Vivo Animal Model; H&E Staining; Western Blot; Clinical Sample Validation; Bioinformatics Analysis; RT-ddPCR
Clinical significance:

C190 is a negative prognostic biomarker of lung cancer; elevated C190 levels were associated with tumor size, aggressiveness, metastasis, low survival rate, advanced-stage lung cancer, and poor outcome of anti-PD-L1 treatment.
Description:

hsa_circ_0000190 (C190), a CNIH4-derived human circRNA, is up-regulated in NSCLC tumor tissues and lung cancer cell lines and acts as an oncogenic mediator of EGFR-MAPK-ERK signaling. C190 promotes ERK1/2 activation, cell-cycle and global translation-associated kinase activity, proliferation, migration, survival, and xenograft tumor growth, partly through sponging miR-142-5p to relieve repression of CDK6/CDKs. Its elevated expression is associated with advanced disease and poor clinical outcome, and CRISPR/Cas13a-mediated C190 knockdown suppresses tumor progression.
Confidence score:

0.8446
Other information
Title:

Oncogenic circRNA C190 Promotes Non-Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway.

Journal: Cancer research
Published: 2022
PubMed ID: 34753774
Study type:

combined biological and clinical study
Data availability: TCGA-LUAD; Supplementary Tables S1-S6; Supplementary Table S4; Supplementary Table S6; circBase database (http://www.circbase.org/); TargetScan tool (http://www.targetscan.org/vert_72/); CircInteractome database (http://circinteractome.nia.nih.gov)
Code availability: -